Saturday, October 10, 2015 4:17:55 PM
CALA
http://www.thestreet.com/story/13307419/5/5-stocks-insiders-love-right-now.html
Calithera Biosciences (CALA) , which focuses on discovering and developing small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer in the U.S. Insiders are buying this stock into massive weakness, since shares have plunged by 68.3% over the last six months.
Calithera Biosciences has a market cap of $93 million and an enterprise value of $12.8 million. This stock trades at a reasonable valuation, with a price-to-book of 1.04. Its estimated growth for this year is 58.5%, and for next year it's pegged at -51%. This is a cash-rich company, since the total cash position on its balance sheet is $77.7 million and its total debt is zero.
A beneficial owner just bought 106,968 shares, or about $644,000 worth of stock, at $6 to $6.07 per share.
This stock has just started to spike higher right off some near-term support at $4.91 a share. That spike is starting to push shares of Calithera Biosciences within range of triggering a big breakout trade above some key near-term overhead resistance levels.
If you're bullish on Calithera Biosciences, then I would look for long-biased trades as long as this stock is trending above some key near-term support levels at $4.91 or at $4.31 and then once it breaks out above some near-term overhead resistance levels at $5.66 to $6.29 a share and then above more resistance at $6.78 to $6.82 a share with high volume. Look for a sustained move or close above those levels with volume that hits near or above its three-month average action of 612,211 shares. If that breakout triggers soon, then this stock will set up to re-test or possibly take out its next major overhead resistance levels at $8 to $9 a share, or even $10.50 a share.
Its lead product candidate includes CB-839, an inhibitor of glutaminase, which is in three Phase I clinical trials for the treatment of patients with solid tumors, leukemias, lymphomas, and multiple myeloma. The company has a license agreement with Mars, Inc. to develop and commercialize Symbioscience's portfolio of arginase inhibitors for use in human healthcare. Calithera Biosciences, Inc. was founded in 2010 and is headquartered in South San Francisco, California.
CALA
http://www.thestreet.com/story/13307419/5/5-stocks-insiders-love-right-now.html
Calithera Biosciences (CALA) , which focuses on discovering and developing small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer in the U.S. Insiders are buying this stock into massive weakness, since shares have plunged by 68.3% over the last six months.
Calithera Biosciences has a market cap of $93 million and an enterprise value of $12.8 million. This stock trades at a reasonable valuation, with a price-to-book of 1.04. Its estimated growth for this year is 58.5%, and for next year it's pegged at -51%. This is a cash-rich company, since the total cash position on its balance sheet is $77.7 million and its total debt is zero.
A beneficial owner just bought 106,968 shares, or about $644,000 worth of stock, at $6 to $6.07 per share.
This stock has just started to spike higher right off some near-term support at $4.91 a share. That spike is starting to push shares of Calithera Biosciences within range of triggering a big breakout trade above some key near-term overhead resistance levels.
If you're bullish on Calithera Biosciences, then I would look for long-biased trades as long as this stock is trending above some key near-term support levels at $4.91 or at $4.31 and then once it breaks out above some near-term overhead resistance levels at $5.66 to $6.29 a share and then above more resistance at $6.78 to $6.82 a share with high volume. Look for a sustained move or close above those levels with volume that hits near or above its three-month average action of 612,211 shares. If that breakout triggers soon, then this stock will set up to re-test or possibly take out its next major overhead resistance levels at $8 to $9 a share, or even $10.50 a share.
Its lead product candidate includes CB-839, an inhibitor of glutaminase, which is in three Phase I clinical trials for the treatment of patients with solid tumors, leukemias, lymphomas, and multiple myeloma. The company has a license agreement with Mars, Inc. to develop and commercialize Symbioscience's portfolio of arginase inhibitors for use in human healthcare. Calithera Biosciences, Inc. was founded in 2010 and is headquartered in South San Francisco, California.
CALA
Join the InvestorsHub Community
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
